Janux Therapeutics, Inc. (NASDAQ: JANX) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -0.91 | Insider Own | - | Shs Outstand | 60.98M | Perf Week | -1.04% |
| Market Cap | 925.13M | Forward P/E | - | EPS next Y | -2.68 | Insider Trans | -0.02% | Shs Float | 57.09M | Perf Month | 3.48% |
| Enterprise Value | 894.88M | PEG | 0.24 | EPS next Q | - | Inst Own | - | Short Float | 11.30% | Perf Quarter | 5.57% |
| Income | -111.39M | P/S | 42.80 | EPS this Y | -87.36% | Inst Trans | - | Short Ratio | 5.76 | Perf Half Y | 9.69% |
| Sales | 21.61M | P/B | 1.01 | EPS next Y | -57.36% | ROA | -11.13% | Short Interest | 6.45M | Perf YTD | 9.93% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | -11.85% | 52W High | 35.69 -57.07% | Perf Year | -37.39% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -16.15% | 52W Low | 12.24 25.17% | Perf 3Y | 15.01% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 3.57% - | Gross Margin | -80.84% | Volatility | 5.10% 4.22% | Perf 5Y | -50.28% |
| Dividend TTM | - | EV/Sales | 41.40 | EPS Y/Y TTM | 28.91% | Oper. Margin | -726.34% | ATR (14) | 0.68 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 17.01 | Sales Y/Y TTM | 36.36% | Profit Margin | -529.67% | RSI (14) | 47.32 | Recom | 2.33 |
| Dividend Gr. 3/5Y | - | Current Ratio | 17.01 | EPS Q/Q | -2.63% | SMA20 | -4.19% | Beta | 2.48 | Target Price | 22.60 |
| Payout | 0.00% | Debt/Eq | 0.02 | Sales Q/Q | - | SMA50 | 1.85% | Rel Volume | 0.48 | Prev Close | 15.17 |
| Employees | 109 | LT Debt/Eq | 0.02 | Earnings | Aug 06 | SMA200 | -9.90% | Avg Volume | 1.06M | Price | 15.32 |
| IPO Date | Jun 11, 2021 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 29.16% -14.32% | Net Debt/EBITDA | 0.27 | Volume | 510,506 | Change | 0.99% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jun-25-26 | Reiterated | Truist Financial | $26 | |
| May-11-26 | Reiterated | Evercore ISI | $23 → $22 | |
| May-08-26 | Reiterated | Wedbush | Outperform | $36 |
| Apr-20-26 | Downgrade | Barclays | Overweight → Underweight | $29 → $14 |
| Apr-15-26 | Downgrade | UBS | Buy → Neutral | $57 → $15 |
| Jan-20-26 | Downgrade | Clear Street | Buy → Hold | |
| Jan-16-26 | Reiterated | Piper Sandler | Overweight | $30 |
| Dec-17-25 | Reiterated | Barclays | Overweight | $47 → $29 |
| Dec-02-25 | Reiterated | UBS | $57 | |
| Dec-02-25 | Reiterated | Stifel Nicolaus | $46 → $38 |
Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 15 | 10 | 11 | 8 | 9 | 4 | 0 | 0 | |
| Cost of Goods Sold Incl. D&A | 4 | 2 | 2 | 2 | 1 | 26 | 0 | 0 | |
| Gross Profit | 13 | 8 | 9 | 6 | 8 | -23 | 0 | 0 | |
| Selling, General and Administrative Excl. Other | 26 | 42 | 41 | 26 | 22 | 10 | 2 | 1 | |
| Research and Development | 53 | 126 | 68 | 55 | 53 | 26 | 3 | 3 | |
| Other Operating Expense | 0 | -2 | -2 | -2 | 0 | -26 | 0 | 0 | |
| Operating Income | -66 | -158 | -99 | -73 | -67 | -33 | -5 | -4 | |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Unusual Expense | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 21 | 44 | 30 | 15 | 4 | 0 | -2 | 0 | |
| Net Income Before Taxes | -45 | -114 | -69 | -58 | -63 | -33 | -7 | -4 | |
| Income Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Consolidated Net Income | -45 | -114 | -69 | -58 | -63 | -33 | -7 | -4 | |
| Net Income From Continuing Operations | -45 | -114 | -69 | -58 | -63 | -33 | -7 | -4 | |
| Net Income | -45 | -114 | -69 | -58 | -63 | -33 | -7 | -4 | |
| EPS (Recurring) | -0.91 | -1.83 | -1.28 | -1.32 | -1.52 | -0.79 | -0.16 | -0.10 | |
| EPS (Basic, Before Extraordinaries) | -0.91 | -1.83 | -1.28 | -1.32 | -1.52 | -0.79 | -0.16 | -0.10 | |
| EPS (Diluted) | -0.91 | -1.83 | -1.28 | -1.32 | -1.52 | -0.79 | -0.16 | -0.10 | |
| EBITDA | -41 | -112 | -67 | -56 | -62 | -33 | -7 | -4 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 55.15 | 85.56 | 262.83 | 59.02 | 60.00 | 202.23 | — | — | |
| Gross Margin | 86.67 | 80.00 | 81.82 | 75.00 | 88.89 | -575.00 | — | — | |
| Operating Margin | -440.00 | -1,580.00 | -900.00 | -912.50 | -744.44 | -825.00 | — | — | |
| Net Margin | -300.00 | -1,140.00 | -627.27 | -725.00 | -700.00 | -825.00 | — | — | |
| Shares Outstanding | 54 | 62 | 54 | 44 | 41 | 41 | 42 | 42 | |
| Market Capitalization | 827 | 856 | 2,891 | 472 | 540 | 809 | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Campbell David Alan | President and CEO | Jul 08 '26 | Option Exercise | 4.21 | 7,000 | 29,470 | 388,582 | Jul 10 |
| Doyle Janeen Noel | Chief Corp. & Bus. Dev. Ofcr | Jun 02 '26 | Sale | 14.03 | 4,059 | 56,944 | 75,941 | Jun 04 |
| Dobek Maria | Vice President, Accounting | May 11 '26 | Sale | 14.17 | 2,038 | 28,878 | 32,270 | May 13 |
| Meyer Andrew Hollman | Chief Business Officer | Jan 02 '26 | Sale | 13.73 | 1,879 | 25,799 | 83,095 | Jan 02 |
| DiRaimondo Thomas | Chief Scientific Officer | Jan 02 '26 | Sale | 13.73 | 2,505 | 34,394 | 124,425 | Jan 02 |
| Campbell David Alan | President and CEO | Jan 02 '26 | Sale | 13.73 | 8,072 | 110,829 | 284,982 | Jan 02 |
| Winter Charles M. | Chief Technical Officer | Jan 02 '26 | Sale | 13.73 | 2,401 | 32,966 | 77,721 | Jan 02 |
| McIver Zachariah | Chief Medical Officer | Jan 02 '26 | Sale | 13.73 | 2,714 | 37,263 | 23,286 | Jan 02 |
| Dobek Maria | Vice President, Accounting | Jan 02 '26 | Sale | 13.73 | 1,462 | 20,073 | 15,373 | Jan 02 |
| Meyer Andrew Hollman | Chief Business Officer | Dec 01 '25 | Option Exercise | 10.59 | 3,333 | 35,296 | 88,307 | Dec 03 |
| Meyer Andrew Hollman | Chief Business Officer | Dec 01 '25 | Sale | 32.98 | 3,333 | 109,929 | 84,974 | Dec 03 |
| Meyer Andrew Hollman | Chief Business Officer | Nov 14 '25 | Option Exercise | 10.59 | 3,333 | 35,296 | 88,307 | Nov 14 |
| Meyer Andrew Hollman | Chief Business Officer | Nov 14 '25 | Sale | 30.00 | 3,333 | 99,990 | 84,974 | Nov 14 |
| Meyer Andrew Hollman | Chief Business Officer | Oct 28 '25 | Option Exercise | 6.76 | 16,665 | 112,689 | 98,804 | Oct 30 |
| Meyer Andrew Hollman | Chief Business Officer | Oct 28 '25 | Sale | 30.06 | 16,665 | 500,987 | 82,139 | Oct 30 |